News Room

17-06-2008
CSL Receives TGA Approval to Register Panvax®, Avian Flu Vaccine
CSL Limited announced today that it has received approval from the Australian Therapeutic Goods Administration (TGA) to register Panvax®, CSL’s avian influenza vaccine. Developed by CSL in collaboration with the Australian government, Panvax is intended for use in the prevention of influenza caused by a pandemic strain of avian influenza virus. More.